Can't Veiw this Email? - Click Here
header1 header2
April 2014
Review : ELRIG  “Research & Innovation – Impact into Cancer” conference, Telford, 11th March’14

Conference Director, Mike Jowett and his Scientific Committee excelled themselves by bringing together a variety of high-calibre speakers for the three tracks :

  • Cancer: New Approaches to Understanding the Disease
  • Technologies & Innovation for Phenotypic Screening
  • Bioactive Chemistry: Harvesting the Bounty of Nature

Delegate feedback on the range & content was excellent.

Returning to the Telford International Centre for our 2nd R & I meeting.  The venue provides us with 3 good auditoria, a vibrant exhibition hall, innovation zone and posters area.  The food was exceptional once again.

254 delegates attended, with 26 exhibitors and 25 posters.

View the our gallery and full review here

  Our Technology Prize was won by The Electrospinning Co voted for by the delegates for their 3D Cell Culture Scaffolds.  Presented by Conference Director, Mike Jowett.   The Feedback Survey Prize of a Nook HD was won by Pratima Chennuri from the Open University.   The Poster Prize was won by Bernhard Ellinger, voted for by the Scientific Committee at the show for his Poster:  ‘A phenotypic screening toolbox permits the identification of novel compounds with Anti-Cancer properties derived from Marine Fungi’.    
  Upcoming Events  
Announcing the establishment of a landmark collaboration between AstraZeneca and the UK Medical Research Council
To establish the AZ MRC UK Centre for Lead Discovery within the Discovery Sciences laboratories in the new research building at the Cambridge Biomedical Campus. This collaboration will see MRC scientists working permanently alongside AstraZeneca scientists in the AstraZeneca HTS department. AstraZeneca will provide access to our compound collection and HTS infrastructure; MRC will fund all operational costs associated with supporting academic projects. It is envisaged that up to 15 projects each year will enter the facility following the completion of assay development in academia. While this collaboration is focussed primarily at traditional HTS projects, MRC scientists will have access to compounds and infrastructure to support phenotypic screening if such projects are selected by the MRC. We believe this is a truly unique collaboration that will enable academic researchers to access industry leading compound collection and screening infrastructure. This collaboration represents a further demonstration of AstraZeneca’s commitment to open innovation, it embraces our mission of pushing the boundaries of science to create new medicines, and will support our objectives of creating a vibrant research environment in Cambridge.

For More Information please contact:
Jackie Howard,  ELRIG
Mobile: 07879 050555

Click here for Automatic Subscription to our Newsletter: Subscribe to our Newsletter